Alefacept therapy produces remission for patients with chronic plaque psoriasis ?>

Alefacept therapy produces remission for patients with chronic plaque psoriasis

Alefacept therapy produces remission for patients with chronic plaque psoriasis on ResearchGate, the professional network for scientists. Alefacept was effective as a monotherapy for chronic plaque psoriasis (CPP) in several clinical studies. Ellis et al. conducted a phase II, multicenter, randomized controlled trial of 229 patients who received 1 of 3 doses of intravenous (IV) alefacept (0. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 148(4):784-8 (2003 Apr). New insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.

PSORIASIS is chronic a disease that shows up in form of inflamed, red, dry scaly patches on skin 2New insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis. Individual is 18 years of age or older with chronic moderate to severe plaque psoriasis (Ps) with either of the following: Plaque Ps involving greater than five percent body surface area (BSA); or. Alefacept therapy produces remission for patients with chronic plaque psoriasis. 2Krueger, G.G., Ellis, C.N. Alefacept therapy produces remission for patients with chronic plaque psoriasis.

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study. ArticlePubMed; Krueger GG, Ellis CN: Alefacept therapy produces remission for patients with chronic plaque psoriasis. 1 Most of the traditional therapies available till now, aim at producing clinical improvement of the disease without targeting the factors that cause psoriasis. 14 Multiple courses of alefacept are effective in patients with moderate to severe chronic plaque psoriasis. PASI achieved after 24 weeks of therapy, ranged from 70-91 days and appeared to be dose-related i.e. remission is maintained longer in higher dose group compared to the lower. A double blind study showing disease remission in psoriatic patients was reported by Ellis in 1986. Cyclosporine produces an excellent response in most psoriatics and is an ideal agent for use as short-term monotherapy (1-2 years), in combination therapy, or as part of rotational therapy. They concluded that intramuscular administration of alefacept is a well-tolerated and effective therapy for chronic plaque psoriasis and thus represents a convenient alternative to intravenous dosing.

Adalimumab Improves Health-related Quality Of Life In Patients With Moderate To Severe Plaque Psoriasis Compared With The United States General Population Norms: Results From A Randomized, Controlled Phase Iii Study

PSORIASIS is chronic a disease that shows up in form of inflamed, red, dry scaly patches on skin 3Alefacept is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) mammalian cell expression system. AMEVIVE is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. BACKGROUND: Alefacept has demonstrated efficacy in clinical trials of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities such as phototherapy. Lymphocytes are the target of other therapies including efalizumab and alefacept. This results, for example, in the increased loss of water through the epidermis and makes psoriatic skin more susceptible to physical and chemical irritation, contributing to itching and irritation. Patients want a safe, convenient therapy that will rapidly clear their disease and keep it in remission. Only around a third of patients with chronic plaque psoriasis achieve and maintain good disease control when acitretin is used as monotherapy although its efficacy in pustular and erythrodermic psoriasis is higher.

Adalimumab Improves Health-related Quality Of Life In Patients With Moderate To Severe Plaque Psoriasis Compared With The United States General Population Norms: Results From A Randomized, Controlled Phase Iii Study